newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO)